Reversal of adriamycin resistance with chimeric anti-ganglioside G(M2)

International Journal of Cancer

Volumn 67, Issue 5, 1996, Pages 676-680

  Fukumoto, Hisao ^a   Nishio, Kazuto ^a   Ohta, So ^b   Hanai, Nobuo ^b   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; DOXORUBICIN; GANGLIOSIDE GM2; MESSENGER RNA; N ACETYLGALACTOSAMINYLTRANSFERASE;

ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; COMPLEMENT SYSTEM PROTEINS; DOXORUBICIN; DRUG RESISTANCE; G(M2) GANGLIOSIDE; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; N-ACETYLGALACTOSAMINYLTRANSFERASES; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0029761303     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960904)67:5<676::AID-IJC14>3.0.CO;2-3     Document Type: Article

References (23)

1. COLE, S.P., BHARDWAJ, G., GERLACH, J.H., MACKIE, J.E., GRANT, C.E., ALMQUIST, K.C., STEWART, A.J., KURZ, E.U., DUNCAN, A.M. and DEELEY, R.G., Over-expression of a transporter gene in a multidrug-resistant human lung-cancer cell line. Science, 258, 1650-1654 (1992).
2. COLE, S.P., CHANDA, E.R., DICKE, F.P., GERLACH, J.H. and MIRSKI, S.E., Non-P-glycoprotein-mediated multidrug resistance in a small-cell-lung-cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res., 51, 3345-3352 (1991).
3. COWAN, K.H., BATIST, G., TULPULE, A., SINHA, B.K. and MYERS, C.E., Similar biochemical changes associated with multidrug resistance in human breast-cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc. nat. Acad. Sci. (Wash.), 83, 9328-9332 (1986).
4. M2. J. biol. Chem., 266, 24038-24043 (1991).
5. DOHI, T., NAKAMURA, K., HANAI, N., TAOMOTO, K. and OSHIMA, M., Reactivity of a mouse/human chimeric anti-GM2 antibody KM966 with brain tumors. Anticancer Res., 14, 2577-2581 (1994).
6. M2 in gastric cancer and normal gastric mucosa. J. biol. Chem., 265, 7880-7885 (1990).
7. HONG, W.S., SAIJO, N., SASAKI, Y., MINATO, K., NAKANO, H., NAKAGAWA, K., FUJIWARA, Y., NOMURA, K. and TWENTYMAN, P.R., Establishment and characterization of cisplatin-resistant sub-lines of human lung-cancer cell lines. Int. J. Cancer, 41, 462-467 (1988).
8. HORICHI, N. and 10 OTHERS, 3′-deamino-3′-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks. Cancer Res., 50, 4698-4701 (1990).
9. KASAHARA, K., FUJIWARA, Y., NISHIO, K., OHMORI, T., SUGIMOTO, Y., KOMIYA, K., MATSUDA, T. and SAIJO, N., Metallothionein content correlates with the sensitivity of human small-cell-lung-cancer cell lines to cisplatin. Cancer Res., 51, 3237-3242 (1991).
10. KUBOTA, N., NISHIO, K., TAKEDA, Y., OHMORI, T., FUNAYAMA, Y., OGASAWARA, H., OHIRA, T., KUNIKANE, H., TERASHIMA, Y. and SAIJO, N., Characterization of an etoposide-resistant human ovarian-cancer cell line. Cancer Chemother. Pharmacol., 34, 183-190 (1994).
11. A2 synthesis for utilization of lactosylceramide substrate in vivo. J. biol. Chem., 269, 29227-29231 (1994).
12. MINATO, K., KANZAWA, F., NISHIO, K., NAKAGAWA, K., FUJIWARA, Y. and SAIJO, N., Characterization of an etoposide-resistant human small-cell-lung-cancer cell line. Cancer Chemother. Pharmacol., 26, 313-317 (1990).
13. D2 gangliosides. J. biol. Chem., 267, 12082-12089 (1992).
14. D2 gangliosides. J. biol. Chem., 269, 7045 (1994).
15. NAKAGAWA, K., SAIJO, N., TSUCHIDA, S., SAKAI, M., TSUNOKAWA, Y., YOKOTA, J., MURAMATSU, M., SATO, K., TERADA, M. and TEW, K.D., Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. J. biol. Chem., 265, 4296-4301 (1990).
16. M2 antibody with anti-tumor activity. Cancer Res., 54, 1511-1516 (1994).
17. OHTA, S., HONDA, A., TOKUTAKE, Y., YOSHIDA, H. and HANAI, N., Anti-tumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3. Cancer Immunol. Immunother., 36, 260-266 (1993).
18. OVERTON, W.R., Modified histogram subtraction technique for analysis of flow-cytometry data. Cytometry, 9, 619-626 (1988).
19. PORTOUKALIAN, J., ZWINGELSTEIN, G. and DORE, J.F., Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Europ. J. Biochem., 94, 19-23 (1979).
20. TRENTESAUX, C., LAPLACE, B., MADOULET, C., REBEL, G. and JARDILLIER, J.C., Enhanced sialylation of the K562 cell-surface membrane glycoconjugates induced by adriamycin. Anticancer Res., 7, 187-192 (1987).
21. TRITON, T.R. and YEE, G., The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science, 217, 248-250 (1982).
22. YATES, A.J., THOMPSON, D.K., BOESEL, C.P., ALBRIGHTSON, C. and HART, R.W., Lipid composition of human neural tumors. J. Lipid Res., 20, 428-436 (1979).
23. D2 synthase mRNA in human gastrointestinal cancer. Cancer, 75, 1273-1280 (1995).